公司简介
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic ...
关联新闻
- Jazz Pharmaceuticals to acquire Actio Biosciences for $820 million, expanding rare epilepsy portfolio
Jazz Pharmaceuticals will acquire Actio Biosciences, Inc. for $820 million. Deal centers around Actio's lead drug for KCNT+ epilepsy, ABS-1230.
- Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio
Jazz Pharmaceuticals said on Monday it would buy privately held Actio Biosciences in a deal valued at up to $1.32 billion, adding an experimental treatment for a rare inherited form of epilepsy that...